Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States

A Multicenter Study

Li-Ming Zhu, MD, Laura Tang, MD, PhD, Xin-Wei Qiao, MD, Edward Wolin, MD, Nicholas N. Nissen, MD, Deepi Dhall, MD, Jie Chen, MD, Lin Shen, MD, Yihebali Chi, MD, Yao-Zong Yuan, MD, Qi-Wen Ben, MD, Bin Lv, MD, Ya-Ru Zhou, MD, Chun-Mei Bai, MD, Jie Chen, MD, Yu-Li Song, MD, Tian-Tian Song, MD, Chong-Mei Lu, MD, Run Yu, MD, PhD, and Yuan-Jia Chen, MD

Abstract: The presentation, pathology, and prognosis of pancreatic neuroendocrine tumors (PNETs) in Asian patients have not been studied in large cohorts. We hypothesized that the clinicopathological features of PNETs of Chinese patients might be different from those of US patients. The objectives of this study were to address whether PNETs in Chinese patients exhibit unique clinicopathological features and natural history, and can be graded and staged using the WHO/ENETS criteria.

This is a retrospective review of medical records of patients with PNETs in multiple academic medical centers in China (7) and the United States (2). Tumor grading and staging were based on WHO/ENETS criteria. The clinicopathological features of PNETs of Chinese and US patients were compared. Univariate and multivariate analyses were performed to find associations between survival and patient demographics, tumor grade and stage, and other clinicopathological characteristics.

A total of 977 (527 Chinese and 450 US) patients with PNETs were studied. In general, Chinese patients were younger than US patients (median age 46 vs 56 years). In Chinese patients, insulinomas were the most common (52.2%), followed by nonfunctional tumors (39.7%), whereas the order was reversed in US patients. Tumor grade distribution was similar in the 2 countries (G1: 57.5% vs 55.0%; G2: 38.5% vs 41.3%; and G3: 4.0% vs 3.7%). However, age, primary tumor size, primary tumor location, grade, and stage of subtypes of PNETs were significantly different between the 2 countries. The Chinese nonfunctional tumors were significantly larger than US ones (median size 4 vs 3 cm) and more frequently located in the head/neck region (54.9% vs 34.8%). The Chinese and US insulinomas were similar in size (median 1.5 cm) but the Chinese insulinomas relatively more frequently located in the head/neck region (48.3% vs 26.1%). Higher grade, advanced stage, metastasis, and larger primary tumor size were significantly associated with unfavorable survival in both countries.

Several clinicopathological differences are found between Chinese and US PNETs but the PNETs of both countries follow a similar natural history. The WHO tumor grading and ENETS staging criteria are applicable to both Chinese and US patients.

Introduction

Pancreatic neuroendocrine tumors (PNETs) are a group of uncommon tumors arising in the endocrine pancreas but the incidence of these tumors has increased worldwide.1–6 They are classified into subgroups accordingly to various criteria.1,2,5 Based on whether they cause clinical hormonal excess syndromes, the PNETs are classified as functional or nonfunctional. Using proliferative markers, PNETs are categorized as low-, intermediate-, or high-grade.7–9 Using the TNM (tumor, node, and metastasis) system, PNETs are divided into 4 stages of tumor advancement.8–10 PNETs grade and stage are the major determinants of prognosis.10
The above tumor taxonomy has largely been based on PNETs in European and US patients. PNETs are well known in Asian countries although the epidemiology is not clearly characterized.\textsuperscript{11-16} There have not been large studies of PNETs in Asian patients. The presentation, pathology, and prognosis of PNETs in Asian patients are not clearly described due to the limited number of patients in existing studies. It is not known whether PNETs in Asian patients exhibit unique natural history or can be graded and staged using available criteria.

The most populous and third largest country, China probably has the greatest PNET burden per country.\textsuperscript{11-14} We thus retrospectively compared the presentation, pathology, and prognosis of PNETs in Chinese and US patients in a multicenter study.

METHODS

Data Retrieval

A total of 977 patients with histological diagnosis of PNETs from 1983 to 2012 at each participating hospital were studied; these included 344 patients from Peking Union Medical College Hospital, 32 from Cancer Institute and Hospital of Chinese Academy of Medical Sciences, 24 from Beijing Cancer Hospital, all in Beijing, 7 from the Third Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, all in the north of China; 60 from the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 54 from Ruijin Hospital of Shanghai Jiao Tong University, Shanghai, 6 from the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, all in the south of China; 342 from Memorial Sloan Kettering Cancer Center, New York, and 108 from Cedars-Sinai Medical Center, Los Angeles, both in United States. The patients’ electronic or paper medical records were reviewed and clinical history, laboratory test results, imaging studies, and pathological reports were analyzed and extracted. This study has been approved by the Institutional Review Board of the respective participating centers.

Diagnosis and Treatment

The diagnosis and management approaches were dictated by the local standards but were mostly similar.\textsuperscript{11-14} Briefly, diagnosis of PNETs was suspected if the patients exhibited a hormonal excess syndrome and imaging identified pancreatic or liver masses, or the patients had pancreatic or liver masses either incidentally discovered or found during the workup of abdominal symptoms. In either case, biopsy of the pancreatic mass or liver lesions was done to establish the diagnosis of PNETs. For treatment, the pancreatic PNET and liver metastatic lesions were resected whenever possible, followed by locoregional therapy of residual liver lesions and systemic therapy composed of a somatostatin analog and other medications. Additional therapy was dictated by the treating physicians and by availability.

Pathological Classification

Tumor grading and staging were performed based on the ENETS criteria.\textsuperscript{9,10} For grading, both mitotic index and Ki-67 labeling were measured; when the results were discordant, the higher grade assigned by either was defined as the grade of the tumor. For staging, the TNM system was used.

Statistical Analysis

Student t test, x\textsuperscript{-}test or Fisher exact test, and Mann–Whitney method were used. Logistic regression was used for multivariate analysis. Survival of patients was analyzed by the Kaplan–Meier method and Cox proportional hazard model. Two-tailed test was used in all statistical analyses. $P \leq 0.05$ was considered significant.

RESULTS

General Description of PNETs

PNET Presentation

Four of the 7 Chinese centers locate in Northern part of China, and 3 in Southern China, respectively. The 2 US centers locate in the East and West Coast of the United States, respectively. The 977 patients’ clinical information is summarized in Tables 1 and 2. Their median age was 51 but the Chinese patients were about 10 years younger than the US patients. Slightly more patients were female (55.5%), especially in China (59.0% vs 51.4% in United States, $P = 0.0196$). Cumulatively, more patients harbored nonfunctional tumors (NF) than functional ones but most of the patients with NF were from US centers. Among the 527 Chinese patients, only 209 had NF (39.7%), while among the 450 US patients, 345 did (76.7%). Of the functional tumors, insulinomas were the most common in both countries, followed by gastrinomas and glucagonomas, and insulinomas were the predominant tumor type in Chinese patients (52.2%). In both countries, the vast majority of patients had sporadic PNETs and ~5% had familial syndromes such as multiple endocrine neoplasia type 1 (MEN1) and von Hippel-Lindau disease (VHL). Although about 60% of all the primary tumors located at the body or tail while the remainder at the head or neck of pancreas, the Chinese PNETs had an even distribution (49.6% vs 49.0%, Table 1) and 2/3 of US PNETs were at the body/tail region. At presentation, 32.4% of patients already had metastasis but the Chinese patients had less metastasis than US counterparts (28.0% vs 38.4%, $P = 0.0013$, Table 1), mostly due to that the Chinese had larger number of insulinomas that do not usually metastasize. Most patients underwent surgical resection of the primary tumor or liver metastatic lesions but <5% did not due to extensive tumor burden. The most common site of distant metastases was liver, followed by bone, lung, and kidney. One Chinese patient with NF exhibited metastasis to scalp skin.

PNET Grade and Stage

Overall 72.1% of the PNETs had a Ki-67 labeling index \(\leq 2\%\) and there was a small difference in the percentage of tumors with Ki-67 labeling index \(\leq 2\%\) in Chinese and US patients (69.7% vs 74.8%). As mitotic index was also used to grade PNETs, tumors with G1 grade were fewer than those with a Ki-67 labeling index \(\leq 2\%), The Chinese and US patients had similar distribution of G1 (57.7% vs 55.0%), G2 (38.3% vs 41.3%), and G3 (4.0 vs 3.7%) PNETs (Table 1). At presentation, most tumors were at stage I, IIA, or IV in both Chinese and US patients, and the Chinese patients had more tumors at stage I or IIA than US patients (61.2% vs 50.3%, $P = 0.0074$, Table 1).

Analysis of PNET Prognosis

Of the 977 patients, 722 (73.9%) had follow-up data, and 688 of the 722 patients underwent surgical resection. The median follow-up period was 42 months. Kaplan–Meier analysis showed that stage, grade, Ki-67 labeling index, and metastasis were significantly associated with overall survival.
TABLE 1. Summary of Clinicopathological Characteristics of 977 Patients With Pancreatic Neuroendocrine Tumors

| Clinicopathological Features of PNETs | All Patients | China | US |
|--------------------------------------|--------------|-------|-----|
| **Gender n (%), n = 971**            |              |       |     |
| Male                                 | 432 (44.5)   | 216 (41.0) | 216 (48.6) |
| Female                               | 539 (55.5)   | 311 (59.0) | 228 (51.4) |
| Male:female                          | 1:1.25       | 1:1.44 | 1:1.06 |
| **Age at surgery in years, n = 977** |              |       |     |
| Median (range)                       | 51 (12–88)   | 46 (12–85) | 56 (12–88) |
| Mean ± SD                            | 50.0 ± 14.7  | 45.7 ± 14.1 | 55 ± 13.6 |
| **Functional type n (%), n = 977**   |              |       |     |
| Functional                            | 421 (43.1)   | 318 (60.3) | 103 (22.9) |
| Nonfunctional                         | 554 (56.7)   | 209 (39.7) | 345 (76.7) |
| Mixed                                 | 2 (0.2)      | 0 (0) | 2 (0.4) |
| **PNET subtype n (%), n = 977**      |              |       |     |
| Insulinoma                            | 328 (33.6)   | 275 (52.2) | 53 (11.8) |
| Noninsulinoma                         | 649 (66.4)   | 252 (47.8) | 397 (88.2) |
| Gastrinoma                            | 44 (4.5)     | 21 (4.0) | 23 (5.1) |
| Glucagonoma                           | 28 (2.9)     | 16 (3.0) | 12 (2.7) |
| VIPoma                                | 15 (1.5)     | 6 (1.1) | 9 (2.0) |
| Others                                | 8 (0.8)      | 0 (0) | 8 (1.8) |
| **Inheritance n (%), n = 974**       |              |       |     |
| Sporadic                              | 932 (95.7)   | 508 (96.9) | 424 (94.2) |
| MEN-1                                 | 35 (3.6)     | 15 (2.9) | 20 (4.4) |
| VHL                                   | 5 (0.5)      | 1 (0.2) | 4 (0.9) |
| Mahvash disease                       | 2 (0.2)      | 0 (0) | 2 (0.4) |
| **Surgical treatment n (%), n = 961** |              |       |     |
| Resection                             | 911 (94.8)   | 474 (90.5) | 437 (100) |
| Nonresection                          | 50 (5.2)     | 50 (9.5) | 0 (0) |
| **Primary tumor site n (%), n = 933** |              |       |     |
| Head or neck                          | 396 (42.4)   | 248 (49.6) | 148 (34.2) |
| Body or tail                          | 530 (56.8)   | 245 (49.0) | 285 (65.8) |
| Nonpancreas                           | 7 (0.8)      | 7 (1.4) | 0 (0) |
| **Tumor size n (%), n = 925**         |              |       |     |
| <2 cm                                 | 321 (34.7)   | 184 (36.4) | 137 (32.6) |
| ≥2 cm                                 | 604 (65.3)   | 321 (63.6) | 283 (67.4) |
| <3 cm                                 | 502 (54.3)   | 292 (57.8) | 210 (50.0) |
| ≥3 cm                                 | 423 (45.7)   | 213 (42.2) | 210 (50.0) |
| <4 cm                                 | 616 (66.6)   | 352 (69.7) | 264 (62.9) |
| ≥4 cm                                 | 309 (33.4)   | 153 (30.3) | 156 (37.1) |
| **Metastasis n (%), n = 874**         |              |       |     |
| No                                    | 591 (67.6)   | 365 (72.0) | 226 (61.6) |
| Yes                                   | 283 (32.4)   | 142 (28.0) | 141 (38.4) |
| Lymph node only                       | 69 (7.9)     | 25 (4.9) | 44 (12.0) |
| Distant                               | 188 (21.5)   | 111 (21.9) | 77 (21.0) |
| Liver                                 | 174 (19.9)   | 99 (19.5) | 75 (20.4) |
| Bone                                  | 11 (1.3)     | 7 (1.4) | 4 (1.1) |
| Others                                | 9 (1.0)      | 5 (1.0) | 4 (1.1) |
| **Ki-67 staining n (%), n = 660**     |              |       |     |
| ≤2%                                   | 476 (72.1)   | 244 (69.7) | 232 (74.8) |
| >2%                                   | 184 (27.9)   | 106 (30.3) | 78 (25.2) |
| **Grade n (%), n = 653**              |              |       |     |
| G1                                    | 367 (56.2)   | 173 (57.7) | 194 (55.0) |
| G2                                    | 261 (40.0)   | 115 (38.3) | 146 (41.3) |
| G3                                    | 25 (3.8)     | 12 (4.0) | 13 (3.7) |
| I                                     | 262 (31.1)   | 168 (33.4) | 94 (27.2) |
| IIA                                   | 215 (25.3)   | 135 (26.8) | 80 (23.1) |
| IIIa                                  | 100 (11.8)   | 52 (10.3) | 48 (13.9) |
| IIIb                                  | 10 (1.2)     | 7 (1.4) | 3 (0.9) |
| IV                                    | 71 (8.4)     | 27 (5.4) | 44 (12.7) |
| **Stage n (%), n = 849**              |              |       |     |
| Available                             | 722 (73.9)   | 288 (54.6) | 434 (96.4) |
| **Follow-up information, n (%)**      |              |       |     |
| Post-operation, n = 688               |              |       |     |
| Follow-up months                      | Median (range)| 42 (1–408) | 48 (1–302) | 36 (1–408) |
| Overall survival, n (%)               | 570 (82.8)   | 229 (88.4) | 341 (79.5) |
| Survival (month)                      | Mean/median  | 53.2/42.0 | 56.2/48.0 | 51.5/36.0 |
| Disease-free survival, n (%)          | 448 (65.1)   | 186 (71.8) | 262 (61.1) |
| Alive with disease                    | 119 (17.3)   | 41 (15.8) | 78 (18.2) |
| Alive with unknown status*            | 3 (0.4)      | 2 (0.8) | 1 (0.2) |
| Death, n (%)                          | 118 (17.2)   | 30 (11.6) | 88 (20.5) |
| Dead of PNETs                         | 84 (12.2)    | 26 (10.0) | 58 (13.5) |
| Dead of unknown cause                 | 34 (4.9)     | 4 (1.5) | 30 (7.0) |
Insulinomas and Noninsulinoma PNETs

As insulinomas are the most common functional PNETs, they were analyzed as a single group composed of patients from both countries or separately. A total of 328 patients had insulinoma with most of them from China (n = 275, 83.8%). Noninsulinoma PNETs were the largest subgroup of PNETs, including 649 patients with 61.2% of them from the United States. The median size of insulinomas was the same in Chinese and US patients (1.5 vs 1.5 cm), in contrast, the median size of noninsulinomas was 4.0 and 3.0 cm in Chinese and US patients, respectively (P = 4.2 × 10⁻⁸, Table 2). The Chinese insulinomas relatively more frequently located in the head/neck region (48.3% vs 26.1%). The Chinese and US insulinomas had similar distribution of G1 (68.6% vs 58.3%), G2 (31.4% vs 41.7%), and G3 (0% vs 0%) whereas the distribution of grade was quite different in the noninsulinomas between 2 countries (P = 0.012). In both countries, most insulinomas were at stages I and II. The Chinese insulinoma patients had a trend of lower percentage of stages III and IV combined than US patients (8.4% vs 20.6%, P = 0.102) but this was reversed in patients with noninsulinomas (52.5% vs 37.4%, P = 1.3 × 10⁻⁸, Table 2). The rate of 5- and 10-year OS of Chinese and US insulinoma patients were similar (96.1% vs 96.0%). The rate of 5-year DFS of the Chinese insulinoma patients was slightly higher than that of US patients (95.2% vs 85.6%, P = 0.030) but the rates of 10-year DFS were similar (84.3% vs 85.6%) (Table 2). In contrast, the rate of 5-year DFS of the Chinese noninsulinoma patients was significantly lower than that of US patients (55.4% vs 69.9%, P = 0.003).

DISCUSSION

In this study, we compared the presentation, pathology, and prognosis of PNETs in Chinese and US patients. To our knowledge, this is the first multicenter, systemic study of PNETs in a large cohort of Chinese patients. The use of US patients as control has allowed us to validate the results of the study. We demonstrate interesting differences in the presentation of PNETs and gross similarities in the pathology and prognosis of PNETs among Chinese and US patients.

It may be initially surprising that most Chinese patients had functional while most US patients had nonfunctional PNET (OS) and disease-free survival (DFS) (Figure 1). Female patients had slightly better OS but the difference was only a statistical trend (Suppl. Figure 1, http://links.lww.com/MD/A703). Functional PNETs exhibited better OS and DFS which was mainly influenced by the excellent prognosis of insulinomas (Suppl. Figure 1, http://links.lww.com/MD/A703). Larger primary tumor size was significantly associated with worse prognosis in both Chinese patients and US patients whatever cutoff value, 2-, 3-, or 4 cm, was used (Figure 2 and Suppl. Figure 2, http://links.lww.com/MD/A703). Separate Kaplan–Meier analyses of Chinese and US patients did not reveal significant differences in the relationships between age, sex, functionality, metastasis, Ki-67 labeling index, grade, and stage and OS (Figure 3 and Suppl. Figure 3, http://links.lww.com/MD/A703). The associations of the above variables with survival were generally similar in Chinese and US cohorts separately, the tumor size was not associated with worse OS (P = 0.102, Figure 3F). Multivariate analysis (Cox models) suggested that higher grades, more advanced stages and presence of metastasis were associated with unfavorable OS or DFS (Suppl. Tables 1 and 2, http://links.lww.com/MD/A703). Primary tumor size <3 cm was significantly associated with favorable DFS and a statistical trend of better OS (Suppl. Table 1, http://links.lww.com/MD/A703). When we correlated the primary tumor size with OS in Chinese and US cohorts separately, the tumor size was not associated with OS as the number of patients was smaller in each group (Suppl. Table 2, http://links.lww.com/MD/A703). The associations of the above variables with survival were generally similar in Chinese and US patients (Suppl. Table 2, http://links.lww.com/MD/A703).

Comparison of Clinicopathological Features Between PNET Subgroups of Chinese and US Patients

As one of the aims of the study was to compare the clinicopathological characteristics between Chinese and US PNETs, we further compared different subtypes of Chinese and US PNETs. Age, tumor size, primary location, grade, and stage were significantly different between Chinese and US patients within the same subgroups of PNETs. These data are summarized in Table 2.

Nonfunctional PNETs (NF)

When the Chinese and US patients were considered as a single group, a total of 554 patients had NF with more from United States (n = 345, 62.3%) (Tables 1 and 2). The Chinese NF were significantly larger than United States ones (median range) 4 (1–25) vs 3 (0.2–17) cm; mean ± SD 5.4 ± 3.4 vs 4.0 ± 3.3 cm) and more frequently located in the head/neck region (54.9% vs 34.8%). The Chinese patients had lower percentage of G1 (42.4% vs 55.5%) and higher G3 (11.3% vs 2.7%) tumors than US patients (P = 0.001). The Chinese patients also had lower percentage of stage I (6.4% vs 26.5%) and higher percentage of stage IV (32.2% vs 20.2%) tumors than US patients (P = 1.5 × 10⁻⁷) (Table 2). The rates of 5-year OS of Chinese and US patients were similar (91.1% vs 93.3%) whereas the rate of 10-year OS of Chinese patients was modestly but significantly higher (88.9% vs 73.4%). The rates of DFS were similar in the Chinese and US patients: 63.6% vs 66.9% at 5 years, and 59.6% vs 61.1% at 10 years (Table 2).

Clinicopathological Features of PNETs

| Without resection, n = 29 survival (month) | All Patients | China | US |
|--------------------------------------------|--------------|-------|----|
| Mean/median                                | 24.3/14.0    | 24.3/14.0 | NA |
| Alive with disease                         | 24 (82.8)    | 24 (82.8) | NA |
| Dead of PNETs                              | 4 (13.8)     | 4 (13.8) | NA |
| Dead of unknown cause                      | 1 (3.4)      | 1 (3.4)  | NA |

MEN-1 = multiple endocrine neoplasia type 1, PNET = pancreatic neuroendocrine tumor, SD = standard deviation, VHL = von Hippel-Lindau disease.

Three patients are alive but it is not clear whether they had disease or not.
### TABLE 2. Comparison of Clinicopathological Features of Subtypes of Pancreatic Neuroendocrine Tumors in Chinese and US Patients

| Clinical Features | Nonfunctional PNET | Functional PNET | Noninsulinoma PNET | Insulinoma PNET |
|-------------------|--------------------|-----------------|--------------------|----------------|
| Gender            |                    |                 |                    |                |
| Male              | n = 209            | n = 209         | n = 243            | n = 275        |
| Female            | 87 (41.7)          | 77 (42.0)       | 169 (55.1)         | 110 (44.0)     |
| Male/female       | 1:1.40             | 1:1.04          | 1:1.47             | 1:1.48         |
| Age at surgery    | n = 209            | n = 209         | n = 228            | n = 275        |
| Median (range)    | 9 (1.2–84)         | 46 (1–85)       | 43 (1–85)          | 46 (1–84)      |
| Mean ± SD         | 45.8 ± 14.1        | 55.0 ± 16.7     | 46.5 ± 13.8        | 56 ± 12.5      |
| Genetics          | n = 206            | n = 206         | n = 228            | n = 275        |
| Spondee           | 202 (98.1)         | 330 (95.7)      | 242 (97.2)         | 266 (96.7)     |
| Primary tumor site| n = 195            | n = 195         | n = 228            | n = 275        |
| Head/neck (H/N)   | 107 (54.9)         | 118 (34.8)      | 121 (88.7)         | 127 (84.3)     |
| Body/tail (B/T)   | 88 (45.1)          | 221 (65.2)      | 107 (96.2)         | 133 (65.4)     |
| H/N/B/T           | 1:0.82             | 1:1.87          | 1:1.11             | 1:1.07         |
| PNET size, cm     | n = 197            | n = 197         | n = 208            | n = 275        |
| Median (range)    | 4 (1–25)           | 3 (0.2–17)      | 4 (0.1–10)         | 4 (0.4–10)     |
| Mean ± SD         | 5.4 ± 3.4          | 4.0 ± 3.3       | 2.1 ± 2.0          | 2.1 ± 2.0      |
| Metastasis        | n = 201            | n = 201         | n = 228            | n = 275        |
| No                | 118 (58.3)         | 131 (62.9)      | 121 (50.4)         | 122 (40.6)     |
| Yes               | 83 (41.3)          | 77 (37.1)       | 119 (49.6)         | 129 (59.4)     |
| Ki-67 staining    | n = 121            | n = 121         | n = 228            | n = 275        |
| <2%               | 68 (56.2)          | 192 (76.5)      | 77 (55.0)          | 166 (79.4)     |
| >2%               | 53 (43.8)          | 59 (23.5)       | 53 (45.0)          | 43 (20.6)      |
| Grade             | n = 106            | n = 106         | n = 123            | n = 275        |
| I                 | 45 (42.4)          | 16 (55.5)       | 53 (42.4)          | 120 (69.4)     |
| II                | 49 (46.2)          | 122 (41.8)      | 60 (48.0)          | 55 (31.4)      |
| III               | 12 (11.3)          | 8 (2.7)         | 12 (9.6)           | 0 (0)          |
| Stage             | n = 202            | n = 202         | n = 128            | n = 275        |
| I                 | 13 (6.4)           | 26 (72.6)       | 155 (55.0)         | 153 (58.2)     |
| II                | 90 (39.0)          | 20 (72.4)       | 99 (41.3)          | 88 (33.5)      |
| III               | 7 (2.3)            | 9 (12.4)        | 32 (13.3)          | 2 (0.8)        |
| IV                | 65 (22.8)          | 22 (30.1)       | 49 (39.2)          | 20 (7.6)       |
| Prognosis (%)     | n = 101            | n = 101         | n = 123            | n = 275        |
| Overall survival  | 89 (88.1)          | 268 (86.2)      | 104 (90.9)         | 126 (95.5)     |
| DOD               | 12 (11.9)          | 43 (13.8)       | 14 (9.1)           | 6 (4.5)        |
| 5-year survival   | 91.1%              | 93.3%           | 95.8%              | 96.4%          |
| 10-year survival  | 88.9%              | 73.4%           | 86.0%              | 86.0%          |
| DFS               | 60 (59.4)          | 214 (68.8)      | 128 (62.9)         | 120 (92.3)     |
| 5-year DFS        | 63.6%              | 69.9%           | 84.8%              | 10 (7.7)       |
| 10-year DFS       | 59.6%              | 61.1%           | 76.3%              | 84.3%          |

AWD = alive with disease, DFS = disease-free survival, DOD = died of disease, MEN-1 = multiple endocrine neoplasia type 1, PNET = pancreatic neuroendocrine tumor, SD = standard deviation, VHL = von Hippel-Lindau disease.
FIGURE 1. Kaplan–Meier analysis of overall survival and disease-free survival of patients with PNETs. Left panels are the overall survival curves and right panels are disease-free survival curves. (A and B) Influence of tumor stage. Blue, green, red, and purples lines represent patients with stages I, II, III, and IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients with G1, G2, and G3 PNETs, respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs with Ki-67 labeling index ≤2% and >2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without and with metastasis, respectively.
FIGURE 2. Kaplan–Meier analysis of overall survival and disease-free survival of Chinese and US patients in relation to tumor size. (A–F) Overall survival; (G–L) disease-free survival. Green and blue lines represent patients with tumors <2 and ≥2 cm, respectively (A, B, G, and H), <3 and ≥3 cm, respectively (C, D, I, and J), and <4 and ≥4 cm, respectively (E, F, K, and L).
FIGURE 3. Comparison of Kaplan–Meier analyses of overall survival of Chinese and US patients. Left panels are the curves of Chinese and right panels of US patients. (A and B) Influence of tumor stage. Blue, green, red, and purples lines represent patients with stage I, II, III, and IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients with G1, G2, and G3 PNETs, respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs with Ki-67 labeling index ≤2% and >2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without and with metastasis, respectively.
FIGURE 4. Comparison of Kaplan–Meier analyses of disease-free survival of Chinese and US patients. Left panels are the curves of Chinese and right panels of US patients. (A and B) Influence of tumor stage. Blue, green, red, and purple lines represent patients with stage I, II, III, and IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients with G1, G2, and G3 PNETs, respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs with Ki-67 labeling index ≤2% and >2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without and with metastasis, respectively.
(NF) but evolution of the epidemiology of NF in the United States suggests that the smaller NF case numbers in Chinese patients may be due to a detection bias. NF used to be considered rare in US populations as well but has become more common than functional tumors in recent years. At Mayo Clinic, the percentage of NF increases from 15% between 1960 and 1978 to 53% between 1985 and 1993.17,18 Similarly, at MD Anderson Cancer Center, the percentage of NF increases from 44% between 1950 and 1987 to 91% between 2001 and 2009.19,20 The same increase of the frequency of NF is also observed at Massachusetts General Hospital.5,15 The increase of the frequency of NF is most likely due to early detection of NF by sensitive imaging modalities such as CT and MRI before the tumor causes clear symptoms. In China where sophisticated imaging is currently probably not as widely used as in the United States,22,23 early detection of NF is thus less likely, explaining its apparent lower relative incidence than that of functional tumors. On the other hand, we cannot rule out that NF is genuinely uncommon in China. Future epidemiological studies of PNETs in Chinese patients would clarify this issue.

Although most Chinese patients with PNETs were middle-aged, like the US patients, the apparent younger age of presentation of insulinomas and NF in Chinese patients is intriguing. As there are no known environmental or behavioral factors contributing to PNETs pathogenesis, it is presumptive to discuss factors that make Chinese PNET patients present at younger ages. However, there could be several potential underlying causes of this phenomenon. The Chinese patients may be genetically more susceptible to PNETs, thus presenting at a younger age. Since more Chinese NFs locate in pancreatic head or neck where the tumors tend to cause symptoms earlier than tumors at pancreatic body or tail, Chinese NF patients may thus present at an earlier age. Moreover, the mean age of NF in Chinese patients was relatively larger than that of US patients, which also results in symptoms at earlier stage of the tumor. Another possible explanation of the younger age of Chinese patients with PNETs is that the life expectancy of Chinese people (74.8 years) is about 3 years shorter than that of US people (78.2 years), so that older Chinese patients who would otherwise be diagnosed with PNETs may die of other causes before being diagnosed. Interestingly, the age of patients with PNETs in the United States is getting older since 1960s. For example, at MD Anderson Cancer Center, the mean age of patients with PNETs used to be younger as well but grew from 49 years between 1950 and 1987 to 58 years between 2001 and 2009.19,20 The higher female to male ratio in Chinese PNET patients (1.44:1) is different from the equal sex distribution in US patients (1.44:1) is different from the equal sex distribution in US patients but similar to the sex ratio (female to male: 1.6:1) by our present finding that almost twice as much Chinese NF received these medications but unfortunately the accurate data are not available to us. Our study thus cannot reliably address the survival benefits of somatostatin analogs. Our study has several limitations. As described earlier, we did not have data on detailed systemic treatment on most Chinese patients. This is a retrospective study with the intrinsic shortcomings of a retrospective study. The Chinese and US patient populations contain uneven proportions of functional tumors and NF, making the comparison of overall PNET prognosis less feasible. We used survival, a more definitive measure of prognosis, but did not have data on patients’ symptoms and quality of life, which are both important measures of prognosis. These limitations, however, do not diminish the value of our main findings.

In summary, this multicenter, cross-Pacific study of nearly 1000 patients with PNETs demonstrates that the symptom-based diagnostic workup thus mostly identifies larger tumors and tumors at the head/neck of pancreas, which are more common in the Chinese patients. Before the advent of frequent imaging procedures in the United States, NFs were also larger than those seen in contemporary practice. At Massachusetts General Hospital, for example, the average size of NFs decreases from 5.6 cm between 1977 and 1999 to 4.1 cm between 2000 and 2005.21
contemporary Chinese patients in general are younger, have relatively fewer nonfunctional tumors, and larger tumors than US patients. Tumor grades and stages are also different in subgroups of PNETs between the 2 countries. PNETs in Chinese and US patients likely follow a similar natural history and the ENETS grading and staging criteria are validated in Chinese patients. The same criteria can probably be used in Asian patients at large.

REFERENCES

1. Oberk E, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–781.
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–1492.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after ‘‘carcinoid’’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072.
4. Lawrence B, Gustaffson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. EndocrinoMetab Clin North Am. 2011;40:1–18.
5. Ro C, Chai W, Yu VE, et al. Pancreatic neuroendocrine tumors: biology, diagnosis, and treatment. Chin J Cancer. 2013;32:312–324.
6. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–243.
7. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrinol Relat Cancer. 2011;18:S1–S16.
8. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumors of the Digestive System. 4th ed. Lyon: IARC Press; 2010:13–14.
9. Capelli P1, Fassan M, Scarpa A. Pathology—grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:705–717.
10. Rindi G, Falconi M, Klersey C, et al. TNM staging of neuroendocrine tumors of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764–777.
11. Zhang TP, Zhao YP, Zhu Y, et al. Clinicopathologic features and surgical treatment of non-functional islet cell tumors (78 case report). Zhonghua Yi Xue Za Zhi. 2005;85:2647–2650.
12. Mei M, Deng D, Liu TH, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009;94:3448–3457.
13. Zhao YP, Zhan HX, Zhang TP, et al. Surgical management of patients with insulinomas: results of 292 cases in a single institution. J Surg Oncol. 2011;103:169–174.
14. Wang YH, Yang QC, Lin Y, et al. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore). 2014;93:e247.
15. Kang CM, Kim KS, Choi JS, et al. Experiences with nonfunctional neuroendocrine neoplasms of the pancreas. Dig Surg. 2005;22:453–458.
16. Nomura N, Fujii T, Kanazumi N, et al. Non-functional neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639–647.
17. Kent RB III, van Heerden JA, Weiland LH. Non-functional islet cell tumors. Ann Surg. 1981;193:185–190.
18. Lo CY, van Heerden JA, Thompson GB, et al. Islet cell carcinoma of the pancreas. World J Surg. 1996;20:878–883.
19. Venkatesh S, Ordonez NG, Ajani J, et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990;65:354–357.
20. Atiq M, Bhutani MS, Bektas M, et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2012;57:791–800.
21. Vageli PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg. 2007;142:337–345.
22. Mettler FA Jr, Bhargavan M, Faulkner K, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. 2009;253:520–531.
23. He D, Yu H, Chen Y. Equity in the distribution of CT and MRI in China: a panel analysis. Int J Equity Health. 2013;12:39.
24. Ekeblad S, Skogseid B, DUNDER K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–7805.
25. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–2377.
26. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824–833.
27. Khan MS, Luong TV, Watkins J, et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013;108:1838–1845.
28. Martin RC, Kooby DA, Weber SM, et al. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011;15:175–183.
29. Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044–3049.
30. Ellison TA, Wolfgang CL, Shi C, et al. A single institution’s 26-year experience with non-functional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204–212.
31. Deutsch GB, Lee JH, Bilchik AJ. Long-term survival with long-acting somatostatin analogues plus aggressive cytoreductive surgery in patients with metastatic neuroendocrine carcinoma. J Am Coll Surg. 2015;221:26–36.